ultrasensitive detection of biomarkers
About
Novilux, founded in 2019, has advanced its Single Molecule Counting (SMC™) technology to create a new standard in sensitivity, time-to-result and consumable cost for Point‑of‑Care diagnostics.
Our focus on performance, simplicity and manufacturability has led to:
-
A novel, low‑cost, confocal architecture optimized for single‑photon counting in multiplexed assays.
-
Purpose‑built fluidic and process components - pumps, valves, centrifugal separation, magnetic handlers etc. at 10X lower cost, designed specifically for SMC™ point‑of‑care workflows.
-
A reagent architecture suitable for any immunoassay and blood chemistry testing.
-
A versatile, two‑piece consumable design engineered for scalability and low production costs.
To ensure result integrity, Novilux developed SAFE (System and Assay Fidelity Evaluation), an integrated run‑time QC module using image‑based and photon‑level signal analysis to rigorously monitor each stage of the SMC™ process. In development, SAFE revealed subtle process anomalies, enabling targeted refinements that produced a highly robust and repeatable assay workflow. In commercial operation SAFE (and a positive control) verifies results.
Point‑of‑Care systems run one sample at a time, making new assay development slow and resource‑intensive. To overcome this constraint, Novilux created the Rapid Development Platform (RDP), a multiplexed SMC™ assay development instrument testing of hundreds of samples in parallel. The RDP uses the same internal components as Phoenix and sharply accelerates new content development.
The Result: unprecedented sensitivity, multiplexed biomarker measurement and a robust, rapid, rigorously validated diagnostic process ... delivered cost effectively at the Point‑of‑Care.
Technology Overview
Instruments | Assays | Consumables
Creative Targeted Development
Novilux' innovations in immunoassay design, photon-counting optics, fluidics, consumable architecture, image and signal processing, and reagent chemistry deliver exceptional sensitivity while significantly reducing cost.
-
Simplicity by Design - Novilux begins with a simple consumable consisting of just two components. Eliminating parts, valves, specialized coatings, electronics, and tight tolerances reduces recurring operational costs.
-
Purpose-Built Engineering - Critical instrument subsystems are designed and manufactured in-house. By focusing exclusively on the capabilities required for each subsystem, Novilux avoids unnecessary complexity and 3rd-party profit, resulting in a lower instrument cost.
-
"Instrumenting the Instrument"- Novilux SAFE QC was implemented from the outset. Comprehensive real-time characterization of every step in the process, for every sample, was essential to create an optimized and robust process.
-
Integrated Technologies - Targeted development of multiple technologies was fundamental to create the Phoenix System. Extensive testing using CLSI protocols has proven performance and demonstrated the effectiveness of the approach.
Novilux' technology portfolio is protected by 33 issued patents, with many additional patents pending. IP protection extends through 2040 and beyond, creating a strong and durable competitive barrier.
Team Overview
Testing at the Point-of-Care has potential to simultaneously improve patient care while reducing overall medical costs. But, without skilled technicians to operate equipment it also has the highest demands for ease of use, rigorous run-time quality control, robust operation, and low cost.
The Novilux team has employed their diverse skillset, superb creativity, and collaborative mindset to develop an array of key technologies needed for ultra-high performance while achieving operational simplicity for practitioners at the Point-of-Care.
